Clarifies that product approval from U.S. Food and Drug Administration is not required for drug manufacturer to file registration statement, and specifies timeframe by which DOH must review registration statements.

DSpace Repository

dc.contributor	Compiled by the New Jersey State Library	en_US
dc.date.accessioned	2019-08-01T13:27:48Z
dc.date.available	2019-08-01T13:27:48Z
dc.identifier.uri	http://hdl.handle.net/10929.1/26498
dc.description.abstract	Year: 2016; Chapter: 73
dc.title	Clarifies that product approval from U.S. Food and Drug Administration is not required for drug manufacturer to file registration statement, and specifies timeframe by which DOH must review registration statements.
dc.type	Legislative History	en_US
lg.yearEnacted	2016	en_US
lg.chapter	73	en_US
lg.billNumber	S2024	en_US
lg.synopsis	Clarifies that product approval from U.S. Food and Drug Administration is not required for drug manufacturer to file registration statement, and specifies timeframe by which DOH must review registration statements.
lg.NJSA	24:6B-1 & 24:6B-2	en_US
lg.njlhid	L2016c73	en_US
lg.title	Clarifies that product approval from U.S. Food and Drug Administration is not required for drug manufacturer to file registration statement, and specifies timeframe by which DOH must review registration statements.